Expert Opinion on Therapeutic Targets

Association between plasma levels and immunolocalization of cytokines in heart valve lesions: a possible target for treatment?
pp. 1209-1215(7)
Authors: Toli, Konstantina; Paraskevas, Kosmas I; Poulakou, Maria V; Agrogiannis, Georgios; Kavantzas, Nikolaos; Xanthopoulos, Vassilios; Iliopoulos, Dimitrios G; Mantas, Ioannis; Papachristodoulou, Antonios; Patsouris, Efstratios; Mikhailidis, Dimitri P; Perrea, Despina N

Targeting protein kinase B/Akt signaling with vanadium compounds for cardioprotection
pp. 1217-1227(11)
Authors: Bhuiyan, Md. Shenuarin; Shioda, Norifumi; Fukunaga, Kohji

Targeting angiogenin in therapy of amyotropic lateral sclerosis
pp. 1229-1242(14)
Authors: Kishikawa, Hiroko; Wu, David; Hu, Guo-fu

Targeting topoisomerase I: molecular mechanisms and cellular determinants of response to topoisomerase I inhibitors
pp. 1243-1256(14)
Authors: Beretta, Giovanni Luca; Perego, Paola; Zunino, Franco

Inhibiting angiotensin type 1 receptors as a target for diabetes
pp. 1257-1263(7)
Authors: Kintscher, Ulrich; Foryst-Ludwig, Anna; Unger, Thomas

Targeting glycogen synthase kinase-3 (GSK-3) in the treatment of Type 2 diabetes
pp. 1265-1274(10)
Authors: MacAulay, Katrina; Woodgett, James R

Raf kinase inhibitory protein (RKIP): A physiological regulator and future therapeutic target
pp. 1275-1287(13)
Authors: Zeng, Lingchun; Imamoto, Akira; Rosner, Marsha Rich

Proprotein convertases as therapeutic targets
pp. 1289-1300(12)
Authors: Chrétien, Michel; Seidah, Nabil G; Basak, Ajoy; Mbikay, Majambu

Chromatin-modifying enzymes as therapeutic targets - Part 1
pp. 1301-1312(12)
Authors: Keppler, Brian R; Archer, Trevor K